Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
(4) - EconoTimes)
Add as a preferred source on Google
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
